Controversy over rosiglitazone, a drug used to treat type 2 diabetes that has been linked with sometimes fatal heart-related problems, may be coming to a head as federal regulators are poised to scrutinize evidence about the drug's safety.
Critics of the drug, which is used to lower blood glucose levels, want it removed from the market because meta-analyses and observational studies comparing rosiglitazone with other glucose-controlling drugs have found it is associated with an increased risk of myocardial infarction and cardiovascular death. But others suggest that rosiglitazone should remain a treatment option, at least until results come in from a recently launched randomized controlled trial.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Graphic Jump Location
Some researchers, public health advocates, and government officials want to see how the US Food and Drug Administration addresses safety issues surrounding rosiglitazone.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.